Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

t levels through the close of the merger with Immune.

Other Income (Expense)Other income (expense) in the second quarter of 2013 amounted to net expense of $0.2 million compared with net expense of $0.9 million in the second quarter of 2012.  Other income (expense) in the six months ended June 30, 2013 amounted to net expense of $0.4 million compared with net expense of $1.9 million in the six months ended June 30, 2012.  The primary component of other expense in 2013 was interest expense related primarily to the Company's senior secured term loan.  The primary components of other expense in 2012 were warrant amendment expense of $0.9 million, interest expense of $0.7 million related primarily to the Company's senior secured term loan and a foreign exchange loss of $0.3 million.

About EpiCept CorporationEpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.  The Company's product Ceplene®, when used concomitantly with low-dose IL-2, is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.  The Company sold all of its rights to Ceplene® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda AB in June 2012.  Ceplene® is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene® in all other countries, including countries in North and South America.  The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been show
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 Biotech ... development of emerging drug systems and advanced Laboratory Instrumentation. ... and Company (NYSE: BDX ), Thermo Fisher ... Inc. (NASDAQ: RGDO ), Sangamo Biosciences Inc. ... HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ...
(Date:9/19/2014)... St. Paul, Minnesota (PRWEB) September 19, 2014 ... representatives from related food industries will gather October ... Meeting at the Rhode Island Convention Center in ... exhibition will feature the work of food scientists, ... development, quality control, and food production management. To ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
Breaking Biology Technology:Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... Therapeutics, Inc., a,privately held biopharmaceutical company, announced today ... will present a corporate,overview at the JMP Securities ... 7 at 9 a.m. ET at the Le ... Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company,focused ...
... 1 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix, today announced that it will,host a ... 12:15 p.m. EDT. A,webcast of the presentations will ... PRESENTATIONS, -- Strategic Company Overview, Jonathan Lim, ...
... - OncoGenex,Pharmaceuticals, Inc (NASDAQ: OGXI ) will ... on October 2 at 4:30 pm ET in ... City. OncoGenex, President and,Chief Executive Officer, Scott Cormack, ... a discussion of the Company,s lead cancer drug,candidate ...
Cached Biology Technology:Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... were instrumental in the creation of the Santa Ana ... the fire threat potential of the powerful, hot, dry ... an inferno. The index was introduced Sept. 17 by ... San Diego Gas and Electric. , The index includes ... will be used to help fire agencies and other ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... (UW) researchers have gathered evidence that dangerous plaques in ... are fat-laden rough spots in the otherwise smooth walls ... of it, a process known as plaque hemorrhage. The ... flow of oxygen-rich blood is restricted, a heart attack, ...
... A Brazilian scorpion has provided researchers at North ... venom,s effects on the ability of certain cells to ... understanding diseases like pancreatitis or in targeted drug delivery. ... an inflammation of the pancreas. ECU microbiologist Dr. Paul ...
... Science Foundation has bestowed a Faculty Early Career Development ... molecular biologist and geneticist whose work since she joined ... her passion for research and her commitment to training ... Award is an exceptional recognition of exceptional qualities in ...
Cached Biology News:Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 2Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 3Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 4Scorpion venom provides clues to cause, treatment of pancreatitis 2FSU biologist wins $1M Early Career Award from National Science Foundation 2FSU biologist wins $1M Early Career Award from National Science Foundation 3
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Cord blood endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: